The Army will launch a major research initiative next year on the effectiveness of commonly prescribed medication for PTSD. Speaking at the APA meeting in Philadelphia on Monday, Army Maj. Gary Wynn of Walter Reed and Col. David Benedik, associate director for the Center for the Study of Traumatic Stress at the Uniformed Services University of the Health Sciences, said clinical trials will evaluate medications such as Cymbalta, mirtazapine, prazosin, and atypical antipsychotics like Seroquel.
Related Item:
Army to study use of ‘off label’ drugs to treat PTSD (Stars and Stripes)
